Melatonin in Patients With Multiple Sclerosis (MS).

  • STATUS
    Recruiting
  • End date
    Mar 23, 2022
  • participants needed
    30
  • sponsor
    Providence Health & Services
Updated on 23 January 2021
fumarate
fingolimod
teriflunomide

Summary

To date, there are no published data on the role of melatonin supplementation or the appropriate dose for patients with multiple sclerosis. Because of the potential benefits of melatonin, this pilot study will be an exploratory investigation to evaluate the effect of supplementing melatonin in subjects with multiple sclerosis who are taking an oral disease modifying therapy (DMT) for 6 months or longer. It is our intent that the results of this study will support the rationale and be a prelude to a larger trial which can focus on clinical efficacy of melatonin therapy outcomes.

Description

The primary objective of this study is to evaluate the change in 24 hour urinary 6-sulfatoxymelatonin (6SMT) collected for 24 hours in two twelve hour sessions. The secondary objectives are to evaluate the change in serum morning melatonin level. In addition, quality of life (QOL) measures will be assessed including the Modified Fatigue Impact Scale (MFIS), Multiple Sclerosis Impact Scale (MSIS-29), and the Pittsburgh Sleep Quality Index (PSQI). Clinical objectives include the number of relapses during the trial and a change in the Patient Determined Disease Steps (PDDS) & Performance Scales (PS).

The pilot study is a one-year randomized, rater- and dose-blinded trial evaluating the potential role of melatonin in subjects with relapsing multiple sclerosis who have been taking a stable dose of an oral disease modifying therapy (DMT) for at least 6 months. The oral DMTs include dimethyl fumarate, fingolimod, and teriflunomide. Thirty subjects with relapsing forms of multiple sclerosis who meet all of the eligibility criteria will be enrolled at Providence Neurological Specialties in Portland, Oregon.

Details
Condition Multiple Sclerosis, relapsing-remitting multiple sclerosis, Radiologically Isolated Syndrome, Dermatite Atopique modérée ou grave
Treatment 3 mg Melatonin, 5 mg Melatonin
Clinical Study IdentifierNCT03498131
SponsorProvidence Health & Services
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 65 yrs?
Gender: Male or Female
Do you have relapsing-remitting multiple sclerosis?
Do you have any of these conditions: relapsing-remitting multiple sclerosis or Dermatite Atopique modérée ou grave or Multiple Sclerosis or Radiologically Isolated Syndrome?
Male and female subjects with relapsing forms of MS who have been on a stable dose of dimethyl fumarate, fingolimod, or teriflunomide for 6 months or longer
Confirmed diagnosis of Relapsing MS
Women of childbearing potential must employ proven methods to prevent pregnancy during the course of the trial; the acceptable method will be left to the judgment of the investigator
Not pregnant or lactating
No evidence of significant cognitive or psychiatric disorder
Able to understand the purpose and risks of the study
Must be willing to sign an informed consent and follow the protocol requirements

Exclusion Criteria

Use of melatonin within 30 days of enrollment
The addition of any sleep aide or change in dose within 30 days of enrollment or during the trial
The addition or change in dose of Vitamin D within 30 days of enrollment or during the trial
Change in disease modifying therapy (DMT) during the trial
Steroid therapy within 30 days of enrollment
Use of anticoagulation at the time of enrollment and during the trial
The addition or change in dose of any stimulants, including but not limited to, amantadine, armodafinil, methylphenidate, or modafinil within 30 days of enrollment or during the trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note